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Data on familial risks in penile and vulvar/vaginal cancers and in second primary cancers (Spcs) 
following these cancers are limited. We used the Swedish Family-Cancer Database from years 1958 
through 2015 to identify 3641 penile and 8856 vulvar/vaginal cancers and to calculate relative risks 
(RRs) and 95% confidence intervals (CIs) for these cancers according to site-specific cancer in family 
members; additionally risk for Spcs was calculated. the familial RR for concordant (same) penile cancer 
was 3.22 (1.34–7.74), and it was 2.72 (1.69–4.39) for vulvar/vaginal cancer; RRs were increased for 
vulvar/vaginal cancer in families of anal cancer patients. RR for second penile cancer after penile cancers 
was 11.68 (7.95–17.18), while that for concordant vulvar/vaginal cancer was 9.03 (7.31–11.15). SPCs 
were diagnosed in 16.8% of penile cancer patients and in them 45.9% of deaths were caused by SPC 
(other than penile cancer). In vulvar/vaginal cancer patients with SPC, 36.4% of deaths were due to SPC. 
the results showed that these genital cancers might run in families and as Spcs are associated with 
human papilloma virus and smoking related cancers. Risk for these genital and anal Spcs are high and a 
follow-up plan should be agreed at diagnosis of these cancers.
Microbial infections are estimated to account for 16% of the global cancer burden, and of these 50% of female 
cancers are associated with human papillomavirus (HPV) infection while the share for male cancers is less than 
5%1,2. The cancers for which evidence on the association with HPV infections is strongest include cervical, ano-
genital and a subset of upper aerodigestive tract cancers, particularly tonsillar and oropharyngeal cancers3. Penile 
cancers are very rare, with an incidence of 1.9/100,000 in Sweden4. HPV infections are associated probably with 
most cases and other risk factors include smoking, ultraviolet irradiation, chronic infections, warts and condylo-
mas, phimosis and lack of circumcision5. The 5-year survival of penile cancer is around 70% in Europe and USA 
in the early 2000s6,7. The incidence of vulvar and vaginal cancers is 4.4/100,000, with more than half of tumors 
being located in the vulva, the rest in the vagina and in unspecified locations4. Risk factors for female genital 
cancers are essentially the same as for cervical cancer. HPV accounts for about half of the cases and other risk fac-
tors are immunosuppression, irradiation, other infections and smoking8–10. In a recent meta-analysis the average 
5-year survival in HPV-positive vulvar cancer was 68% compared to 57% for HPV-negative vulvar cancer10. In 
contrast to many family studies of cervical cancer, data on familial clustering of penile, vaginal and vulvar cancers 
are very limited. In a study on HPV-related cancers published in 2008 we showed a risk for first-degree relatives 
for penile and vulvar cancers, and the latter was also associated with cervical cancer9. Similarly, studies on for 
second primary cancers (SPCs) following male and female genital cancers are rare while those following cervical 
cancer are more common, and generally shown an increased risk of HPV and smoking related sites and cancers 
in anatomic sites close to the cervix, probably as a result of treatment or more wide-spread infection11–13. SPCs 
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following in situ cervical cancers showed the highest risks of anal and vulvar/vaginal cancers but also increased 
risks of upper aerodigestive tract, esophageal, lung and stomach cancers11.
Here we used the current update of the Swedish Family-Cancer Database, the largest family dataset in the 
world, to address familial risks, SPCs and mortality in penile, vulvar and vaginal cancers. For internal consistency 
we assessed familial risks bi-directionally (in reverse order), i.e., risk for penile cancer when family members were 
diagnosed with any cancer, and risk for any cancer when family members were diagnosed with penile cancer. For 
parent-offspring relationships the data are largely independent and confirmed bi-directional associations would 
be evidence for a true biological association. Similarly, risks for SPCs were analyzed bi-directionally, e.g., penile 
cancer either as first cancer or SPC after any other cancer. Mortality data were compared in penile, vulvar and 
vaginal cancers with and without SPCs, focusing on cancer causes of death, as it can be suspected that some SPCs 
are particularly fatal.
Results
The Family-Cancer Database included 3641 penile and 8856 vulvar/vaginal cancers, diagnosed at median ages of 
68 and 73 years, respectively (Table 1). Considering only the offspring generation (born after 1931) the respective 
case numbers were 1278 and 2233 with median ages at diagnosis of 58 and 59 years, respectively. The number of 
SPCs were 610 (16.8%) after penile and 1028 (11.6%) after vulvar/vagina cancers, diagnosed 7 and 5 years (medi-
ans) after the genital cancers.
In reference to RRs, we use the convention that we refer to risks only when they are significant, i.e., the 95%CIs 
do not overlap with the reference RR of 1.00. Accordingly, it is redundant to repeat 95%CIs in the text as these 
anyway are shown in the tables.
Table 2 shows familial risk for penile cancer in sons whose first-degree family members were diagnosed with 
any cancer, and in reverse order, the risk of cancer in the offspring generation when father or brother were diag-
nosed with penile cancers. At least 2 penile cancers (or a significant familial risk in any analyses) had to be 
recorded with any cancer in relatives (first column) for the site to be listed. The RR for penile cancer was increased 
to 3.22 when family members were diagnosed with the same (concordant) cancer (p-value < 0.05); familial cases 
were 2 brother pairs and 3 father-son pairs. The only other significant association of 3.30 was with bone cancer. In 
the reverse analysis, risk for any cancer in offspring when family members were diagnosed with penile cancer, the 
RRs for ovarian cancer (1.60) and thyroid gland tumors (1.79) were significant. As penile cancer is a rare cancer, 
no more but a single penile cancer was found in families of discordant cancers. Thus the number contributing 
families matches the number of ‘Familial cases’ given as the first column in Table 2.
Table 3 shows familial risk for vulvar/vaginal cancer in daughters whose first-degree family members were 
diagnosed with any cancer, and in reverse order, the risk of cancer in the offspring generation when mother or 
sister were diagnosed with vulvar/vaginal cancers. The combined numbers of familial cases were about two times 
higher than in Table 2. The RR for vulvar/vaginal cancer was increased to 2.72 when family members were diag-
nosed with the same cancer (p-value < 0.0001); familial cases were 6 sister pairs and 11 mother-daughter pairs. 
The other significant associations were with anal (2.38), liver (1.34), nasal (2.68) and lung (1.32) cancers. In the 
reverse analysis, RRs for anal (2.13), unspecified uterine (1.98) and bladder (1.29) cancers were increased. Similar 
to penile cancer in Table 2, the number of contributing families is equal to the number of ‘Familial cases’ given as 
the first column.
Risks for SPCs are shown in Table 4 after penile cancer (i.e., in survivors of penile cancer) and for penile can-
cer as the SPC (i.e., in survivors of any primary cancer). Only risks of penile (11.68) and anal (3.97) cancers were 
increased. In the reversed analysis, risk for penile cancer was not increased after any other cancer.
In Table 5 SPCs after vulvar/vaginal cancers were analyzed, with significant risks for upper aerodigestive tract 
(2.26), anal (10.31), lung (1.81), cervical (2.38), vulvar/vaginal (9.03) and connective tissue cancers (3.64). In the 
reverse order, risks for vulvar/vaginal cancers were increased after anal (2.31), cervical (4.20), endometrial (1.52) 
and unspecified uterine cancers (2.13).
In Table 6 data are shown for concordant SPCs after primary penile (i.e., second penile cancer after primary 
penile cancer) and vaginal/vulvar cancer according to the follow-up time. The highest risk of second penile can-
cer was 16.23 at > 5 years of follow-up. For second vulvar/vaginal cancer the highest RR of 9.16 was reached at 
follow-up of >5 years but the RRs were quite uniform throughout.
Causes of death in genital cancer patients are reported in Table 7. For penile cancer in patients without SPC, 
65.7% of deaths were due to non-neoplastic causes and 28.4% were due to penile cancer; 5.9% were caused by can-
cers which were reported in death notifications but not in the cancer registry. For vulvar/vaginal cancers, 43.5% of 
Primary cancer site N (all/offspring) Median age at diagnosis (years)
Penile cancer 3641/1276 68
Vulvar/vaginal cancer 8856/2233 73
Second primary cancer N (%) Median follow-up time (years)
After penile cancer 610a (16.8) 7
After vulvar/vaginal cancer 1028b (11.6) 5
Table 1. The number and age at diagnosis of patients with penile cancer and vulvar/vaginal cancer and number 
of patients with second primary cancer. aThe number of second primary cancer in the offspring generation was 
178, median follow-up time are 6 years. bThe number of second primary cancer in the offspring generation was 
271, median follow-up time are 6 years.
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deaths were caused by vulvar/vaginal cancer and 45.3% were due to non-neoplastic causes. For male patients with 
SPC, 45.9% of deaths were caused by SPC (other than penile cancer), higher order primaries accounted for 4.8% 
of deaths and non-neoplastic causes 32.9%. For female patients, SPCs (other than vulvar/vaginal cancers) caused 
36.4% of deaths, higher order primaries 3.1% and non-neoplastic cause 32.4%.
Causes of death in penile cancer patients are listed according to the type of SPC (Supplementary Table 1). 
Prostate, lung and colorectal cancers as SPC caused the highest numbers of deaths due to SPC. The most fatal 
SPCs were pancreatic (15 of 17 total deaths) and esophageal cancer (7 of 8 total deaths). Similar data for vulvar/
vaginal cancer patients are shown in Supplementary Table 2. Breast, colorectal and lung cancers as SPC caused 
the highest numbers of deaths due to SPC. The most fatal SPC was lung cancer (60 of 74 total deaths) but also 
pancreatic and esophageal cancers claimed a high toll.
Discussion
The present results confirmed the previous findings on concordant familial risk for penile cancer and vulvar/vag-
inal cancers with larger case numbers9. These risks were at the equal magnitude, 3.22, for penile cancer (p < 0.05) 
and 2.72 for vulvar/vaginal cancer (p < 0.0001) but with three times more familial cancers for the latter which 
also showed more than 2 times higher overall case numbers. Penile cancers were associated in single analyses with 
bone, ovarian and thyroid cancers but as solitary results there was no support against chance findings. Vulvar/vag-
inal cancers were associated bi-directionally with anal cancer families and uni-directionally with liver, nasal, lung, 
unspecified uterine and bladder cancer families. Both penile cancer and vulvar/vaginal cancer showed the highest 
risks as respective SPCs, together with high risk of anal cancer which for women was bi-directional. Cervical 
cancer was also bi-directionally associated with vulvar/vaginal cancer as SPC. Upper aerodigestive tract, lung 
and connective tissue cancers were increased as SPCs after vulvar/vaginal cancer, and the risk for vulvar/vaginal 
Cancer site family member
RR for penile cancer RR for cancer
Familial cases RR 95% CI Familial cases RR 95% CI
Upper aerodigestive tract 19 1.07 0.68–1.68 21 1.21 0.79–1.85
Esophagus 8 1.20 0.60–2.41 6 1.01 0.46–2.26
Stomach 33 1.08 0.76–1.53 16 1.24 0.76–2.03
Small intestine 3 0.82 0.26–2.54 2 0.55 0.14–2.21
Colorectum 100 1.11 0.91–1.37 62 0.84 0.65–1.07
Anus 1 0.56 0.08–4.01 1 0.46 0.06–3.25
Liver 27 1.29 0.88–1.89 9 0.67 0.35–1.28
Pancreas 27 1.23 0.84–1.80 16 1.05 0.65–1.72
Nose 0 — — 1 0.88 0.12–6.24
Lung 71 1.23 0.97–1.56 55 1.00 0.76–1.30
Breast (female and male) 98 0.95 0.78–1.17 139 0.97 0.82–1.15
Cervix 20 1.42 0.91–2.20 20 1.33 0.86–2.06
Endometrium 23 1.00 0.66–1.51 21 0.94 0.61–1.44
Uterus, unspecified 3 1.14 0.37–3.55 3 1.16 0.37–3.60
Ovary 22 1.20 0.78–1.82 30 1.60 1.12–2.29
Vulvar/vaginal 6 1.62 0.72–3.61 4 1.51 0.56–4.02
Prostate 124 0.97 0.81–1.17 109 0.82 0.68–0.99
Penile 5 3.22 1.34–7.74
Kidney 17 0.72 0.44–1.15 14 0.73 0.43–1.23
Urinary bladder 37 0.97 0.70–1.35 33 1.10 0.78–1.55
Melanoma 29 1.07 0.74–1.55 51 1.04 0.79–1.36
Skin 38 1.07 0.78–1.48 22 0.85 0.56–1.30
Nervous system 27 1.15 0.78–1.68 43 1.21 0.90–1.64
Thyroid gland 7 1.09 0.52–2.28 17 1.79 1.12–2.89
Endocrine glands 15 1.09 0.65–1.81 13 0.74 0.43–1.28
Bone 4 3.30 1.24–8.81 2 0.76 0.19–3.03
Connective tissue 7 1.37 0.65–2.87 7 1.14 0.55–2.40
Non-Hodgkin lymphoma 22 0.88 0.58–1.34 33 1.21 0.86–1.71
Hodgkin lymphoma 3 0.84 0.27–2.60 3 0.47 0.15–1.46
Myeloma 9 0.76 0.39–1.46 8 0.92 0.46–1.84
Leukemia 20 0.87 0.56–1.35 27 1.07 0.74–1.57
CUPa 23 0.89 0.59–1.34 9 0.48 0.25–0.92
All (including penile) 628 1.12 1.00–1.25 815 0.97 0.91–1.04
Table 2. RRs for penile cancer when family members were diagnosed with any cancer, and RR for cancer when 
family members were diagnosed with penile cancer. CUPa = cancer of unknown primary. RR = relative risk, 
95% CI = 95% confidence interval, bold font indicates that the lower limit of 95% CI does not include 1.00.
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cancer was increased as SPC after endometrial and unspecified uterine cancers. Finally, we showed that SPCs had 
implications for mortality. SPCs were diagnosed in 16.8% of penile cancer patients and in these patients 45.9% of 
deaths were caused by SPC (other than penile cancer) compared to 32.9% of deaths due to non-neoplastic causes, 
which were the main cause of deaths (65.7%) in patients without SPC. In vulvar/vaginal cancer patients the effect 
of SPC was not as marked as in men but even in women with SPC, SPC was the main cause of death, accounting 
for 36.4% of all deaths.
Limitations of the study include small case numbers and hence large 95%CIs, even in spite of this being the 
largest study so far conducted on these cancers relating to familial and SPC risks. Another limitation is the lack 
of possibilities for external validation as much of the previous literature originates from the earlier versions of the 
Swedish database. However, as HPV is an important etiological factor for both penile and vulvar/vaginal cancers, 
the equal findings for the two cancers with consistent bi-directional associations should make a strong case for 
biological interpretations. In regard to concordant SPCs it is an acknowledged problem to distinguish recurrent 
primaries from independent primaries, particularly when an infective agent (HPV) is likely to be an overwhelm-
ing oncogenic driver. However the present results showing the higher risks for second penile and vulvar/vaginal 
cancers in longest follow-up time support the notion of independent primaries.
How can we consolidate the findings? Inherited genetic factors are likely to contribute to the associations, and 
for example in cervical cancer certain human leukocyte antigen (HLA) alleles show strong risk14,15. However, we 
Cancer site family member
RR for vulvar/vaginal cancer RR for cancer
Familial cases RRb 95% CIc Familial cases RR 95% CI
Upper aerodigestive tract 32 1.03 0.73–1.47 49 1.18 0.89–1.56
Salivary glands 4 1.23 0.46–3.28 5 1.08 0.45–2.61
Esophagus 9 0.80 0.41–1.53 13 0.90 0.52–1.56
Stomach 63 1.23 0.96–1.58 29 0.94 0.65–1.36
Small intestine 5 0.82 0.34–1.98 7 0.81 0.38–1.69
Colorectum 150 0.98 0.83–1.15 175 0.98 0.85–1.14
Anus 7 2.38 1.14–5.01 11 2.13 1.18–3.85
Liver 48 1.34 1.01–1.78 22 0.68 0.45–1.03
Pancreas 35 0.94 0.67–1.31 38 1.04 0.75–1.42
Nose 6 2.68 1.20–5.97 4 1.48 0.56–3.96
Lung 130 1.32 1.10–1.57 151 1.13 0.96–1.32
Breast (female and male) 166 0.96 0.82–1.13 312 0.94 0.84–1.05
Cervix 24 0.99 0.66–1.48 24 0.71 0.48–1.07
Endometrium 48 1.25 0.94–1.66 62 1.16 0.90–1.48
Uterus, unspecified 2 0.47 0.12–1.89 12 1.98 1.12–3.49
Ovary 27 0.88 0.60–1.29 39 0.89 0.65–1.22
Vulvar/vaginal 17 2.72 1.69–4.39
Prostate 191 0.90 0.77–1.04 273 0.84 0.75–0.95
Testis 3 0.70 0.23–2.17 18 0.92 0.58–1.46
Penile 4 1.51 0.56–4.02 6 1.62 0.72–3.61
Kidney 41 1.03 0.76–1.41 48 1.05 0.79–1.40
Urinary bladder 72 1.12 0.89–1.42 94 1.29 1.05–1.58
Melanoma 57 1.24 0.95–1.61 90 0.80 0.65–0.98
Skin 59 0.98 0.76–1.27 62 0.99 0.77–1.27
Eye 2 0.50 0.12–1.99 5 0.82 0.34–1.96
Nervous system 48 1.23 0.93–1.64 72 0.90 0.72–1.14
Thyroid gland 10 0.91 0.49–1.70 14 0.67 0.39–1.13
Endocrine glands 25 1.08 0.73–1.60 37 0.92 0.66–1.27
Bone 4 1.94 0.73–5.17 2 0.36 0.09–1.43
Connective tissue 11 1.27 0.70–2.30 18 1.30 0.82–2.07
Non-Hodgkin lymphoma 38 0.90 0.66–1.25 65 1.02 0.80–1.30
Hodgkin lymphoma 6 0.98 0.44–2.19 11 0.81 0.45–1.46
Myeloma 19 0.95 0.60–1.49 18 0.86 0.54–1.37
Leukemia 39 1.00 0.73–1.37 44 0.77 0.57–1.03
CUPa 42 0.95 0.70–1.28 32 0.71 0.50–1.00
All (including vulvar/vaginal) 1027 1.05 0.96–1.14 1880 0.95 0.91–1.00
Table 3. RRs for vulvar/vaginal cancer when family members were diagnosed with any cancer, and RR for 
cancer when family members were diagnosed with vulvar/vaginal cancer. CUPa = cancer of unknown primary. 
RRb = relative risk. 95% CIc = 95% confidence interval, bold font indicates that the lower limit of 95% CI does 
not include 1.00.
5Scientific RepoRtS |         (2019) 9:11804  | https://doi.org/10.1038/s41598-019-48399-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
need to consider also the contribution by other non-genetic risk factors, such as HPV-infection and smoking. 
First we note that the study involved many comparisons (over 30 different cancers were included) and chance 
findings are likely. In the same token we need to point out that many case numbers were small and for these the 
power of detection was small16. Formal correction for the number of comparisons, such as Bonferroni correction, 
is not useful for the present kind of data where most risk estimates were underpowered17. Thus we rely on internal 
consistency between bi-directional results and between familial and SPC results, and on biological plausibility. 
The possibility to invoke external consistency is meager because the previous literature largely originates from 
earlier versions of the present data sources. Risks for concordant genital cancers (familial and SPC) suggest the 
HPV-infection is the likely driver together with inherited genetic factors of these associations with a possible 
contribution with life-style factors such as smoking. Such mechanisms would also be plausible explanations for 
the observed association with cervical, lung and upper aerodigestive tract cancers. The increased risk of vulvar/
vaginal cancers as SPC after cervical and unspecified uterine cancers may be caused by side effects of radiation 
after treatment of primary cancers, as suggested in previous studies11–13. Immunosuppression is often suggested to 
be a contributing mechanism for infection-related familial or personal risks8. Based on cancers arising in immu-
nosuppressed patients, squamous cell skin cancer and non-Hodgkin lymphoma are considered hallmark cancers 
of dysfunctional immune system18,19. It is noteworthy that we found no evidence on increased associations of 
penile or vulvar/vaginal cancers with these cancers, in spite of reasonable case numbers; thus immune suppres-
sion appears not to be important in the present context.
How can we rationalize these results? HPV infections are usually sexually transmitted while for a familial risk 
this mode of transmission would be limited to relatively rare events, such as sexual abuse situations. Transmission 
from an infected mother during pregnancy or early childhood may take place but overall such non-sexual trans-
missions are thought to be rare20. We assume that shared life-style is the main explanation to the observed familial 
risks. In our previous studies we reported, for example, that husbands of women with cervical cancer had an 
Cancer site
After penile cancer After other cancers
SPCs RRb 95% CIc SPCs RR 95% CI
Upper aerodigestive tract 19 1.12 0.72–1.76 14 0.64 0.38–1.08
Salivary gland 0 — — 0 — —
Esophagus 8 1.01 0.51–2.02 1 0.37 0.05–2.60
Stomach 24 0.76 0.52–1.14 10 0.51 0.28–0.95
Small intestine 3 1.10 0.35–3.40 1 0.33 0.05–2.34
Colorectum 70 0.90 0.71–1.13 38 0.35 0.26–0.49
Anus 3 3.97 1.28–12.31 4 2.19 0.82–5.84
Liver 14 0.83 0.49–1.39 2 0.29 0.07–1.18
Pancreas 19 1.08 0.69–1.70 0 — —
Nose 0 — — 0 — —
Lung 69 1.23 0.97–1.56 4 0.18 0.07–0.49
Breast 2 1.96 0.49–7.85 1 0.01 0.001–0.04
Prostate 175 0.85 0.73–0.99 123 0.82 0.69–0.99
Testis 2 2.06 0.52–8.25 6 1.64 0.74–3.65
Penile 26 11.68 7.95–17.18
Kidney 12 0.66 0.37–1.16 3 0.14 0.05–0.45
Urinary bladder 47 1.03 0.78–1.37 28 0.57 0.39–0.82
Melanoma 12 0.72 0.41–1.28 19 0.51 0.32–0.79
Skin 46 1.11 0.83–1.49 36 0.70 0.21–0.98
Eye 0 — — 1 0.32 0.04–2.24
Nervous system 9 0.88 0.46–1.69 4 0.20 0.08–0.54
Thyroid gland 0 — — 3 0.32 0.10–0.99
Endocrine glands 3 0.71 0.23–2.21 3 0.14 0.05–0.43
Bone 1 1.77 0.25–12.59 1 0.71 0.10–5.04
Connective tissue 5 1.44 0.60–3.46 4 0.71 0.27–1.88
Non-Hodgkin lymphoma 14 0.75 0.44–1.26 13 0.61 0.36–1.06
Hodgkin lymphoma 2 1.07 0.27–4.26 2 0.62 0.16–2.49
Myeloma 1 0.11 0.01–0.75 2 0.26 0.06–1.03
Leukemia 12 0.65 0.37–1.14 5 0.27 0.11–0.65
CUPa 12 0.67 0.38–1.18 8 0.85 0.43–1.71
All (excluding penile) 584 1.08 1.00–1.18 336 0.42 0.38–0.47
Table 4. RRs of second primary cancers (SPCs) in survivors of penile cancer and other cancers. CUPa = cancer 
of unknown primary. RRb = relative risk. 95% CIc = 95% confidence interval, bold font indicates that the lower 
limit of 95% CI does not include 1.00.
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increase in tobacco and HPV related cancers21. Risks for cervical and other female genital cancers, together with 
upper aerodigestive tract, anal, liver, pancreatic, lung, kidney and urinary bladder cancers were increased in 
women who had children with different men in Sweden22. Similarly for men who had children with different part-
ners, increasing risks were shown for upper aerodigestive tract, lung, urinary bladder and esophageal cancers23. 
Risks for cervical and lung cancers were increased also in Swedish divorced women24.
The results on mortality overall support the moderate survival in the present genital cancers, consistent with 
non-neoplastic causes being the main cause of death, particularly for penile cancers. With improving survival, SPCs 
Cancer site
After vulvar/vaginal cancer After other cancers
SPCs RRb 95% CIc SPCs RR 95% CI
Upper aerodigestive tract 26 2.26 1.54–3.32 14 0.33 0.20–0.56
Salivary gland 1 0.58 0.08–4.12 4 0.72 0.27–1.91
Esophagus 7 1.23 0.59–2.58 0 — —
Stomach 28 0.85 0.59–1.23 15 0.38 0.23–0.63
Small intestine 7 1.80 0.86–3.78 0 — —
Colorectum 119 1.02 0.85–1.22 136 0.65 0.55–0.77
Anus 26 10.31 7.01–15.16 8 2.31 1.16–4.63
Liver 28 0.87 0.60–1.26 5 0.37 0.15–0.88
Pancreas 26 0.91 0.62–1.33 2 0.17 0.04–0.68
Nose 1 0.80 0.11–5.71 0 — —
Lung 81 1.81 1.45–2.25 9 0.22 0.11–0.41
Breast 173 0.92 0.79–1.06 226 0.73 0.64–0.83
Cervix 34 2.38 1.70–3.33 170 4.20 3.61–4.89
Endometrium 37 0.82 0.59–1.13 136 1.52 1.29–1.80
Uterus, unspecified 3 0.67 0.22–2.07 14 2.13 1.26–3.60
Ovary 24 0.73 0.49–1.08 51 1.31 0.99–1.72
Vulvar/vaginal 87 9.03 7.31–11.15
Kidney 28 1.34 0.92–1.94 11 0.27 0.15–0.49
Urinary bladder 45 1.82 1.36–2.44 38 0.40 0.29–0.54
Melanoma 23 0.99 0.66–1.49 34 0.50 0.35–0.69
Skin 59 1.19 0.92–1.54 66 0.66 0.52–0.85
Eye 4 2.15 0.80–5.72 2 0.33 0.08–1.30
Nervous system 17 0.88 0.55–1.41 17 0.45 0.28–0.73
Thyroid gland 8 1.17 0.58–2.34 6 0.34 0.15–0.75
Endocrine glands 12 0.83 0.47–1.46 29 0.71 0.50–1.03
Bone 1 0.83 0.47–1.46 2 0.76 0.19–3.04
Connective tissue 17 3.64 2.26–5.86 6 0.56 0.25–1.24
Non-Hodgkin lymphoma 26 1.04 0.71–1.53 16 0.40 0.24–0.65
Hodgkin lymphoma 4 1.62 0.61–4.33 5 0.83 0.35–2.00
Myeloma 7 0.55 0.26–1.15 6 0.39 0.18–0.88
Leukemia 24 1.02 0.68–1.52 13 0.36 0.21–0.63
CUPa 45 1.20 0.89–1.60 11 0.59 0.33–1.07
All (excluding vulvar/vaginal) 941 1.28 1.20–1.37 1052 0.75 0.70–0.80
Table 5. RRs of second primary cancers (SPCs) in survivors of vulvar/vaginal cancer and other cancers. 
CUPa = cancer of unknown primary. RRb = relative risk. 95% CIc = 95% confidence interval, bold font indicates 
that the lower limit of 95% CI does not include 1.00.
<=1 yra 1–5 yr >5 yr
After penile cancer
Cases RRb 95% CIc Cases RR 95% CI Cases RR 95% CI
5 10.38 4.32–24.95 2 3.51 0.88–14.03 19 16.23 10.33–25.49
After vulvar/vaginal cancer
Cases RR 95% CI Cases RR 95% CI Cases RR 95% CI
22 8.90 5.85–13.50 22 8.92 5.87–13.56 43 9.16 6.79–12.35
Table 6. RRs of second primary penile and vulvar/vaginal cancers by follow-up time. yra = year. RRb = relative 
risk. 95%CIc = 95% confidence interval, bold font indicates that the lower limit of 95% CI does not include 1.00.
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are becoming increasingly common and we showed that they had a negative influence on mortality. Cancers of 
known to be fatal as first primary cancers, such as pancreatic, esophageal and lung cancers, were also fatal as SPC.
In summary, we provide evidence that penile cancers and vulvar/vaginal cancers might be associated in fam-
ilies and as SPCs with HPV and smoking related cancers. Individual counseling about life-style related cancers 
may not be successful but overall health campaigns may bring some benefit. However, risk for concordant penile 
and vulvar/vaginal cancer and anal SPCs are high and a follow-up plan should be agreed at diagnosis of male and 
female genital cancer patients.
Methods
Database and cancer ascertainment. We used the update of The Swedish Family-Cancer Database 
which covered cancer data from 1958 through 2015 and family links over a century25. This Database includes 16 
million individuals, covering the offspring generations born after 1931 and their biological parents (the parental 
generation) in some 4 million nuclear families. Siblings could be identified only in the offspring generation which 
reached a maximal age of 83 years in 2015.
Coverage of cytologically or histologically verified incident cancers is considered to over 90% complete on 
account of compulsory nationwide registration by clinicians and pathologists26,27. Cancer diagnoses were based 
on the 7th or later revisions of the International Classification of Diseases (ICD). In ICD-10, the code for penile 
cancer was C60, for vulvar cancer it was C51 and for vaginal cancer it was C52. The Swedish Cancer Registry 
requests notifications for SPCs which are thought to be independent primary cancers, considering e. g., anatomic 
location, time since the first cancer and histology. For histologically identical cancers at the same organ site the 
independence cannot be clinically judged, and in these cases some SPCs may be recurrences, causing overestima-
tion, However, it is not known how many true SPCs are not notified because the clinician considers them to be 
recurrences, leading to underestimation.
Statistical analysis. Relative risks (RRs) were used to measure cancer risks for penile or vulvar/vaginal 
cancer in the offspring generation according to occurrence of any cancers in their first-degree family members 
(parents or siblings). Risks were assessed for offspring cancer depending on family history. Thus the RR for e.g., 
familial penile cancer was calculated for offspring cases of penile cancer when their family members were diag-
nosed with penile cancer considering their accumulated person-years at risk and compared to offspring penile 
cancers in families where no penile cancers were diagnosed. In the reverse analysis, RR was calculated for cancer 
in offspring when family members were diagnosed with genital cancer. These two types of analyses were partially 
independent, particularly for discordant cancers, and positive results in both analyses provided strong support for 
a true association28. Follow-up was started for each offspring at birth, immigration or January 1st, 1958, whichever 
came latest. Follow-up was terminated on diagnosis of first cancer, death, emigration, or the closing date of the 
study, which was December 31st, 2015. Poisson regression modeling was employed to estimate RRs and corre-
sponding 95% confidence intervals (CI). For concordant familial RRs we calculated additionally the p-values 
to help inference about the significance of the results. Potential confounders, including sex, age group (5-year 
bands), period (5-year bands), socioeconomic status (blue-collar worker, white-collar worker, farmer, private, 
professional, or other/unspecified), residential area (large cities, South Sweden, North Sweden, or unspecified) 
were added to the model as covariates28.
RRs for SPCs were obtained by comparing incidence rates for cancer X as SPC in penile or vulvar/vaginal 
cancer patients with rates for cancer X as first cancer in the general population. In the reverse analyses, RRs were 
calculated for penile or vulvar/vagina cancer as the SPC following any cancer. Follow-up was started at diagno-
sis of the relevant genital cancer and terminated at diagnosis of SPC, emigration, death or December 31, 2015, 
Cause of death
Without second primary cancer
Penile cancer (N%) Vulvar/vaginal cancer (N%)
Penile cancer 625 (28.4) —
Vulvar/vaginal cancer — 2754 (43.5)
Other cancers 131 (5.9) 707 (11.2)
Non-neoplastic 1447(65.7) 2869 (45.3)
All 2203 (100.0) 6330 (100.0)
Cause of death
With second primary cancer
Penile cancer (N%) Vulvar/vaginal cancer (N%)
Penile cancera 45 (9.4) —
Vulvar/vaginal cancera — 145 (17.2)
SPCb non-penile cancer 219 (45.9) —
SPCb non-vulvar/vaginal cancer — 307 (36.4)
Higher order primary 23 (4.8) 26 (3.1)
Other cancers 33 (6.9) 92 (10.9)
Non-neoplastic 157 (32.9) 273 (32.4)
All 477 (100.0) 843 (100.0)
Table 7. Cause of death in penile cancer and vaginal/vulvar cancer with or without second primary cancer. 
Penile cancera = including first primary cancer and second primary cancer. Vulvar/vaginal cancera = including 
first primary cancer and second primary cancer. SPCb = second primary cancer.
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whichever occurred first. Identical follow-up times were applied when genital cancer was considered as SPC. Sex, 
age group, calendar-period, socio-economic status and residential areas were treated as potential confounders 
and were adjusted for in the regression model28.
All cancer related deaths were stratified into penile or vulvar/vagina cancer, SPC, ‘other cancer’ and 
non-neoplastic cause of death. ‘Other cancer’ includes cases diagnosed at the issue of death certificates, referred to 
‘death certificate notifications’29. These notifications are not used by the Swedish Cancer Registry to complement 
cancer data26,29. We have found that the notifications often included multiple cancers and cancer of unknown 
primary (CUP). In our previous studies we have used these as information on metastases30. If the death certificate 
notification matched the organ site of the reported primary cancer it was classified to that site but in most cases 
such an assignment could not be made and the classification was to ‘other neoplasia’28.
All statistical analyses were done with the SAS version 9.4.
ethical statement. The study was approved by the Ethical Committee of Lund University (Reg. No. 
2012/795), Sweden, and the study was conducted in accordance with the approved guidelines not requesting 
informed consent31. The study is national register-based study on anonymous personal data.
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